Global Pharmacology Expert Joins PhytoMedical

Business Wire, Oct 11, 2006

Dr. Jay R. Wiggins, Accomplished Pharmaceutical Researcher with European and North American Drug Discovery and Development Expertise, Joins PhytoMedical Scientific Advisory Board

PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) announced today the addition of pharmacology researcher and drug discovery and development expert, Dr. Jay R. Wiggins, to the Company's Scientific Advisory Board.

"The addition of Dr. Jay R. Wiggins to our Advisory Board is part of our ongoing effort to continue strengthening PhytoMedical's research, management, and advisory groups, all in the interest of assembling the best possible team to help move our compounds towards commercialization," commented Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc.

On September 19, 2006, PhytoMedical announced the appointments of Mr. Gary Branning, Managing Partner and Sr. Vice President of Managed Market Resources and Mr. Rick A. Henson, Vice President, Sales, Vernalis Pharmaceuticals, Inc. to the Company's Board of Directors. Together, the two senior pharmaceutical executives bring over 50 years of combined experience in every facet of drug development and commercialization, ranging from grooming early-stage startups for successful acquisition, to working with Fortune 500 pharmaceutical corporations.

"Dr. Wiggins is an excellent resource for our team, bringing more than 20 years experience in drug discovery, clinical development, pharmacology, and the drug approval process in the United States and Europe," explained Mr. Wujek.

Dr. Jay R. Wiggins' expertise includes managing pre-clinical drug discovery efforts from identification of lead compounds with associated patents, through Investigational New Drug (IND) filings with the FDA and other regulatory authorities.

Dr. Wiggins is responsible for strategic direction, protocol design, analysis and writing of clinical study reports, preparation of literature reviews, and IND, NDA, and CTD submissions, among other responsibilities in his role as Director, Medical Development Group at Berlex, Inc., a division of Schering AG. Schering is a leading, research-based pharmaceutical company, established in 1851 and today boasting global operations through 150 subsidiaries and annual sales of 5.3 billion euros.

Previously, Dr. Jay R. Wiggins served as Associate Director, Department of Pharmacology, at Berlex and was an Associate Professor at the University of South Florida College of Medicine, Department of Pharmacology and Therapeutics.

Dr. Wiggins is a research expert in cardiovascular biology and medicine, and accredited with more than 40 publications in peer-reviewed, industry, and clinical research journals.

Dr. Jay R. Wiggins, earned his Bachelor of Science (BS) degree in Biology cum laude and with departmental honors from Bucknell University, and his Doctoral (PhD) degree in Pharmacology from Columbia University.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO) (Frankfurt Stock Exchange:ET6), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical's first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals.

For obese or overweight individuals, BDC-03's potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body's inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year - nearly one out of every ten health care dollars spent in the United States.